source
- Roche partners with Simcere Zaiming on trispecific T cell engager, $75M upfrontRoche announced a collaboration with Chinese biopharma Simcere Zaiming to develop a trispecific T cell engager aimed at cancer therapy. The agreement includes an upfront payment of $75 million to…
- GSK to start Phase 3 trial of mRNA flu vaccine after strong mid-stage resultsGSK announced it will begin a Phase 3 trial of its mRNA-based influenza vaccine, with enrollment slated to start in September. In a Phase 2 study of 971 adults, the investigational vaccine, which…